Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MMSI
MMSI logo

MMSI Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
71.300
Open
71.090
VWAP
70.64
Vol
456.29K
Mkt Cap
4.22B
Low
69.880
Amount
32.23M
EV/EBITDA(TTM)
14.30
Total Shares
59.65M
EV
4.50B
EV/OCF(TTM)
15.12
P/S(TTM)
2.81
Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.
Show More

Events Timeline

(ET)
2026-04-01
09:40:00
Merit Medical Acquires View Point Medical for Approximately $140M
select
2026-03-24 (ET)
2026-03-24
08:40:00
Medtronic Enters Distribution Agreement with Merit Medical
select
2026-03-16 (ET)
2026-03-16
09:30:00
Merit Medical Launches New Esophageal Stent
select

News

Newsfilter
9.5
04-02Newsfilter
Merit Medical Systems to Release Q1 2026 Financial Results
  • Earnings Release Schedule: Merit Medical Systems plans to announce its financial results for the quarter ending March 31, 2026, after market close on April 30, 2026, demonstrating the company's commitment to transparency and investor communication.
  • Investor Conference Call: On the same day, Merit will hold an investor conference call at 4:30 p.m. Eastern Time, aimed at sharing financial results and addressing investor inquiries, thereby enhancing investor confidence.
  • Company Background: Founded in 1987, Merit focuses on the development, manufacturing, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, and oncology, showcasing its expertise in healthcare technology.
  • Global Workforce: Merit employs approximately 7,600 people worldwide, supported by a domestic and international sales force and clinical support team of over 800 individuals, indicating its extensive reach and service capabilities in the global market.
seekingalpha
8.5
04-01seekingalpha
Merit Medical Acquires View Point Medical for $140M
  • Acquisition Overview: Merit Medical Systems has acquired View Point Medical for a total transaction value of $140 million, with $90 million paid upfront and $25 million due on the first and second anniversaries of the closing date, thereby enhancing its competitive position in the medical device market.
  • Product Innovation Enhancement: View Point Medical manufactures the OneMark Detection Imaging System and OneMark Tissue Markers, which improve tissue localization, allowing surgeons to quickly detect and visualize tissue markers during biopsies, thus enhancing precision in breast cancer surgeries and reducing re-excision rates.
  • Future Growth Projections: Merit Medical projects a revenue growth of 6% to 8% for 2026, and this acquisition will help strengthen its global platforms while divesting DualCap to optimize resource allocation and enhance profitability.
  • Industry Impact Analysis: This acquisition not only enhances Merit’s product portfolio in the medical technology sector but also has the potential to drive technological advancements in breast cancer treatment by improving surgical precision and reducing patient reoperation risks, highlighting its strategic significance.
Newsfilter
8.5
04-01Newsfilter
Merit Medical Acquires View Point Medical for $140 Million
  • Acquisition Overview: Merit Medical Systems has acquired View Point Medical for approximately $140 million, with $90 million paid in cash at closing and two deferred payments of $25 million each scheduled for the first and second anniversaries, enhancing Merit's market position in oncology products.
  • Technological Integration Benefits: The acquisition combines View Point's OneMark® Detection Imaging System with Merit's SCOUT® platform, providing a more precise solution for breast tumor localization, expected to support 1.3 million biopsy procedures annually, improving treatment timeliness and accuracy for patients.
  • Financial Impact Analysis: The acquisition is projected to contribute revenue of $2 million to $4 million in 2026 but will dilute Merit's non-GAAP earnings per share by approximately $0.05, reflecting short-term financial pressure, while long-term revenue growth is anticipated.
  • Market Outlook: Sales of the OneMark system are expected to grow at least 20% annually by 2027, with a 70% non-GAAP gross margin, indicating that while the acquisition may dilute GAAP net income in the short term, it is likely to improve Merit's profitability in the long run.
NASDAQ.COM
7.5
03-24NASDAQ.COM
Medtronic Enters Exclusive Agreement with Merit for BVNA System
  • Exclusive Distribution Agreement: Medtronic has signed an exclusive agreement with Merit Medical Systems to launch the FDA-approved ViaVerte system, which is the first BVNA system with a physician-controlled steerable mechanism aimed at treating chronic vertebrogenic lower back pain, significantly enhancing treatment options for patients.
  • Product Innovation: The unique design of the ViaVerte system allows physicians to precisely target the basivertebral nerve, thereby improving treatment outcomes and further solidifying Medtronic's leadership in the pain intervention space while providing more effective solutions for chronic pain patients.
  • Strengthened Strategic Partnership: This agreement not only expands Medtronic's pain intervention product portfolio but also deepens the ongoing collaboration with Merit, which currently supplies Medtronic with Kyphon Xpander Inflation Syringes and Kyphon KyphoFlex unipedicular steerable balloon catheters used in balloon kyphoplasty procedures.
  • Market Impact: By introducing the ViaVerte system, Medtronic enhances its competitiveness in the chronic pain treatment market, which is expected to attract more patients to its innovative treatment options, thereby driving continued growth in the medical technology sector.
PRnewswire
7.5
03-24PRnewswire
Medtronic Enters Exclusive Agreement with Merit Medical
  • Innovative Treatment Solution: Medtronic has entered into an exclusive distribution agreement with Merit Medical to offer the FDA-cleared ViaVerte™ basivertebral nerve ablation system, which is the first BVNA system with a physician-controlled steerable mechanism, significantly enhancing treatment options for chronic lower back pain patients.
  • Market Demand Response: According to the American Chronic Pain Association, approximately one in three Americans suffer from chronic pain, and the introduction of the ViaVerte™ system will provide these patients with a minimally invasive, same-day outpatient treatment option, addressing the growing market demand.
  • Deepening Strategic Partnership: This agreement not only continues the collaboration between Medtronic and Merit but also enhances Medtronic's leadership in the pain intervention field by incorporating Merit's proprietary technology, thereby diversifying its product portfolio.
  • Long-term Vision: Paolo Di Vincenzo, president of Medtronic's Neuromodulation division, stated that the addition of this new product will further expand their world-leading position in pain interventions, aiming to provide more effective treatment options for patients and physicians.
Newsfilter
7.5
03-24Newsfilter
Medtronic Enters Exclusive Agreement with Merit Medical
  • Innovative Treatment Solution: Medtronic has entered into a distribution agreement with Merit Medical to offer the FDA-cleared ViaVerte™ basivertebral nerve ablation system, which is the first BVNA system with a physician-controlled steerable mechanism, significantly enhancing treatment options for chronic lower back pain patients.
  • Market Demand Response: According to the American Chronic Pain Association, approximately one in three Americans suffer from chronic pain, and the introduction of the ViaVerte™ system will provide these patients with a minimally invasive, same-day outpatient treatment option, addressing the growing market demand.
  • Deepening Strategic Partnership: This agreement not only continues the collaboration between Medtronic and Merit but also integrates Merit's proprietary technology into Medtronic's pain intervention product portfolio, further solidifying its leadership position in the healthcare technology sector.
  • Business Expansion Potential: Medtronic's pain therapy portfolio includes spinal cord stimulation and vertebral augmentation, and the addition of ViaVerte™ will directly meet the demand for new therapies, driving the company's continued growth in the chronic pain treatment market.
Wall Street analysts forecast MMSI stock price to rise
8 Analyst Rating
Wall Street analysts forecast MMSI stock price to rise
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
90.00
Averages
104.63
High
122.00
Current: 0.000
sliders
Low
90.00
Averages
104.63
High
122.00
BTIG
Sam Eiber
Buy
downgrade
$107 -> $100
AI Analysis
2026-04-13
New
Reason
BTIG
Sam Eiber
Price Target
$107 -> $100
AI Analysis
2026-04-13
New
downgrade
Buy
Reason
BTIG analyst Sam Eiber lowered the firm's price target on Merit Medical to $100 from $107 and keeps a Buy rating on the shares as part of a broader research name on Medical Technology. The firm is updating its models to reflect the CMS having announced its proposed rule for the FY27 inpatient prospective payment system which includes, among other things, preliminary commentary and decisions regarding new technology add-on payments, the analyst tells investors in a research note.
Canaccord
Buy
downgrade
$99 -> $90
2026-04-07
Reason
Canaccord
Price Target
$99 -> $90
2026-04-07
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Merit Medical to $90 from $99 and keeps a Buy rating on the shares. The fim updated its model to reflect the View Point Medical acquisition for $140M which expandis its oncology portfolio.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MMSI
Unlock Now

Valuation Metrics

The current forward P/E ratio for Merit Medical Systems Inc (MMSI.O) is 17.64, compared to its 5-year average forward P/E of 25.52. For a more detailed relative valuation and DCF analysis to assess Merit Medical Systems Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
25.52
Current PE
17.64
Overvalued PE
29.00
Undervalued PE
22.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
17.45
Current EV/EBITDA
11.46
Overvalued EV/EBITDA
19.45
Undervalued EV/EBITDA
15.45

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
3.35
Current PS
2.45
Overvalued PS
3.77
Undervalued PS
2.93

Financials

AI Analysis
Annual
Quarterly

Whales Holding MMSI

O
Oberweis Asset Management, Inc.
Holding
MMSI
+38.33%
3M Return
F
Fuller & Thaler Asset Management, Inc.
Holding
MMSI
+12.65%
3M Return
W
Westwood Management Corp.
Holding
MMSI
+7.19%
3M Return
A
Alaska Permanent Fund
Holding
MMSI
+4.16%
3M Return
A
Aristotle Capital Boston, LLC
Holding
MMSI
+3.32%
3M Return
A
AMI Asset Management Corp
Holding
MMSI
+1.44%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Merit Medical Systems Inc (MMSI) stock price today?

The current price of MMSI is 70.73 USD — it has increased 0.27

What is Merit Medical Systems Inc (MMSI)'s business?

Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.

What is the price predicton of MMSI Stock?

Wall Street analysts forecast MMSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MMSI is104.63 USD with a low forecast of 90.00 USD and a high forecast of 122.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Merit Medical Systems Inc (MMSI)'s revenue for the last quarter?

Merit Medical Systems Inc revenue for the last quarter amounts to 393.94M USD, increased 10.92

What is Merit Medical Systems Inc (MMSI)'s earnings per share (EPS) for the last quarter?

Merit Medical Systems Inc. EPS for the last quarter amounts to 0.63 USD, increased 36.96

How many employees does Merit Medical Systems Inc (MMSI). have?

Merit Medical Systems Inc (MMSI) has 7500 emplpoyees as of April 16 2026.

What is Merit Medical Systems Inc (MMSI) market cap?

Today MMSI has the market capitalization of 4.22B USD.